The Damaging Effect of Passenger Mutations on Cancer Progression
Open accessPublished version of a preprint
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Genomic instability and high mutation rates cause cancer to acquire numerous mutations and chromosomal alterations during its somatic evolution; most are termed passengers because they do not confer cancer phenotypes. Evolutionary simulations and cancer genomic studies suggest that mildly deleterious passengers accumulate and can collectively slow cancer progression. Clinical data also suggest an association between passenger load and response to therapeutics, yet no causal link between the effects of passengers and cancer progression has been established. To assess this, we introduced increasing passenger loads into human cell lines and immunocompromised mouse models. We found that passengers dramatically reduced proliferative fitness (∼3% per Mb), slowed tumor growth, and reduced metastatic progression. We developed new genomic measures of damaging passenger load that can accurately predict the fitness costs of passengers in cell lines and in human breast cancers. We conclude that genomic instability and an elevated load of DNA alterations in cancer is a double-edged sword: it accelerates the accumulation of adaptive drivers, but incurs a harmful passenger load that can outweigh driver benefit. The effects of passenger alterations on cancer fitness were unrelated to enhanced immunity, as our tests were performed either in cell culture or in immunocompromised animals. Our findings refute traditional paradigms of passengers as neutral events, suggesting that passenger load reduces the fitness of cancer cells and slows or prevents progression of both primary and metastatic disease. The antitumor effects of chemotherapies can in part be due to the induction of genomic instability and increased passenger load. Cancer Res; 77(18); 4763–72. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 2×
“Proposals to exacerbate passenger deleteriousness include (i) targeting essential cell functions lost by passenger deletions (48); (ii) increasing cytotoxic stress caused by passengers (19); (iii) increasing passenger load via DNA-damaging therapies (49); and (iv) neoantigenic immune therapies (14).”
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
Assessing the evolutionary impact of amino acid mutations in the human genome.
Boyko, A. R., Williamson, S. H., Indap, A. R., Degenhardt, J. D., Hernandez, R. D., Lohmueller, K. E., Adams, M. D., Schmidt, S., Sninsky, J. J., Sunyaev, S. R., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000083 · Cited by 628 · cited 1×
“This is consistent with findings in natural populations where moderately deleterious mutations primarily cause cytotoxic stress via protein misfolding, disbalance, and aggregation (19, 46, 47), and not by abrogating essential gene function.”
Passenger deletions generate therapeutic vulnerabilities in cancer
Muller, F. L., Colla, S., Aquilanti, E., Manzo, V. E., Genovese, G., Lee, J., Eisenson, D., Narurkar, R., Deng, P., Nezi, L., et al. (2012) · Nature · doi:10.1038/nature11331 · Cited by 339 · cited 1×
“Proposals to exacerbate passenger deleteriousness include (i) targeting essential cell functions lost by passenger deletions (48); (ii) increasing cytotoxic stress caused by passengers (19); (iii) increasing passenger load via DNA-damaging therapies (49); and (iv) neoantigenic immune therapies (14).”
Model of effectively neutral mutations in which selective constraint is incorporated
Kimura, M. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.7.3440 · Cited by 254
Transitions to asexuality result in excess amino acid substitutions
Paland, S., & Lynch, M. (2006) · Science · doi:10.1126/science.1118152 · Cited by 232
Research works printed but not linked: 38
- Castro-giner, 2015, The mini-driver model of polygenic cancer evolution, Nat Rev Cancer, 15, 680, 10.1038/nrc3999 · DOI
- Nussinov, 2015, Science Direct “Latent drivers” expand the cancer mutational landscape, Curr Opin Struct Biol, 32, 25, 10.1016/j.sbi.2015.01.004 · DOI
- Merlo, 2006, Cancer as an evolutionary and ecological process, Nat Rev Cancer, 6, 924, 10.1038/nrc2013 · DOI · Paper page
- Bozic, 2016, Quantifying clonal and subclonal passenger mutations in cancer evolution, PLoS Comput Biol, 12, e1004731, 10.1371/journal.pcbi.1004731 · DOI · Paper page
- McFarland, 2013, Impact of deleterious passenger mutations on cancer progression, Proc Natl Acad Sci U S A, 110, 2910, 10.1073/pnas.1213968110 · DOI · Paper page
- McFarland, 2014, Tug-of-war between driver and passenger mutations in cancer and other adaptive processes, Proc Natl Acad Sci U S A, 111, 15138, 10.1073/pnas.1404341111 · DOI · Paper page
- Gabriel, 1993, Muller's ratchet and mutational meltdowns, Evolution, 47, 1744, 10.1111/j.1558-5646.1993.tb01266.x · DOI · Paper page
- Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N Engl J Med, 371, 2189, 10.1056/NEJMoa1406498 · DOI · Paper page
- Birkbak, 2011, Paradoxical relationship between chromosomal instability and survival outcome in cancer, Cancer Res, 71, 3447, 10.1158/0008-5472.CAN-10-3667 · DOI · Paper page
- Sheltzer, 2011, The aneuploidy paradox: costs and benefits of an incorrect karyotype, Trends Genet, 27, 446, 10.1016/j.tig.2011.07.003 · DOI · Paper page
- Andor, 2015, Pan-cancer analysis of the extent and consequences of intratumor heterogeneity, Nat Med, 22, 105, 10.1038/nm.3984 · DOI · Paper page
- Williams, 2008, Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells, Science, 322, 703, 10.1126/science.1160058 · DOI · Paper page
- Weaver, 2007, Aneuploidy acts both oncogenically and as a tumor suppressor, Cancer Cell, 11, 25, 10.1016/j.ccr.2006.12.003 · DOI · Paper page
- Schvartzman, 2010, Mitotic chromosomal instability and cancer: mouse modelling of the human disease, Nat Rev Cancer, 10, 102, 10.1038/nrc2781 · DOI · Paper page
- Yaglom, 2014, Oncogene-triggered suppression of DNA repair leads to DNA instability in cancer, Oncotarget, 5, 8367, 10.18632/oncotarget.2259 · DOI
- Klambauer, 2012, Cn.MOPS: Mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate, Nucleic Acids Res, 40, 1, 10.1093/nar/gks003 · DOI · Paper page
- Guberman, 2011, BioMart Central Portal: an open database network for the biological community, Database, 2011, bar041, 10.1093/database/bar041 · DOI · Paper page
- Eisenberg, 2013, Human housekeeping genes, revisited, Trends Genet, 29, 569, 10.1016/j.tig.2013.05.010 · DOI · Paper page
- Kent, 2002, The human genome browser at UCSC, Genome Res, 12, 996, 10.1101/gr.229102 · DOI · Paper page
- Aceto, 2012, Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion, Breast Cancer Res, 14, R131, 10.1186/bcr3329 · DOI
- Stephens, 2012, The landscape of cancer genes and mutational processes in breast cancer, Nature, 486, 400, 10.1038/nature11017 · DOI · Paper page
- Pedregosa, 2011, Scikit-learn: machine learning in Python, J Mach Learn Res, 12, 2825
- Sherman, 2011, Oncogenes induce senescence with incomplete growth arrest and suppress the DNA damage response in immortalized cells, Aging Cell, 10, 949, 10.1111/j.1474-9726.2011.00736.x · DOI
- Quiles, 2002, Antioxidant nutrients and adriamycin toxicity, Toxicology, 180, 79, 10.1016/S0300-483X(02)00383-9 · DOI · Paper page
- Donahue, 2006, Carcinogens induce genome-wide loss of heterozygosity in normal stem cells without persistent chromosomal instability, Proc Natl Acad Sci U S A, 103, 11642, 10.1073/pnas.0510741103 · DOI
- Fudenberg, 2011, High order chromatin architecture shapes the landscape of chromosomal alterations in cancer, Nat Biotechnol, 29, 1109, 10.1038/nbt.2049 · DOI · Paper page
- Zack, 2013, Pan-cancer patterns of somatic copy number alteration, Nat Genet, 45, 1134, 10.1038/ng.2760 · DOI · Paper page
- Carter, 2006, A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers, Nat Genet, 38, 1043, 10.1038/ng1861 · DOI · Paper page
- Vermeulen, 2013, Defining stem cell dynamics in models of intestinal tumor initiation, Science, 342, 995, 10.1126/science.1243148 · DOI · Paper page
- Duesberg, 2000, Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy, Proc Natl Acad Sci U S A, 97, 14295, 10.1073/pnas.97.26.14295 · DOI · Paper page
- Wang, 2012, Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome, Clin Cancer Res, 18, 5806, 10.1158/1078-0432.CCR-12-0857 · DOI · Paper page
- Frank, 2007, Dynamics of cancer: Incidence, Inheritance, and Evolution, 10.1515/9780691186863 · DOI · Paper page
- Jackson, 1998, The mutation rate and cancer, Genetics, 148, 1483, 10.1093/genetics/148.4.1483 · DOI · Paper page
- Charlesworth, 1993, The effect of deleterious mutations on neutral molecular variation, Genetics, 134, 1289, 10.1093/genetics/134.4.1289 · DOI · Paper page
- Bachtrog, 2004, Adaptive evolution of asexual populations under Muller's ratchet, Evolution, 58, 1403, 10.1111/j.0014-3820.2004.tb01722.x · DOI
- Jordan, 2010, Human allelic variation: perspective from protein function, structure, and evolution, Curr Opin Struct Biol, 20, 342, 10.1016/j.sbi.2010.03.006 · DOI · Paper page
- Lee, 2012, Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics, Biochem Pharmacol, 83, 1013, 10.1016/j.bcp.2011.12.008 · DOI
- Efron, 1979, Bootstrap methods: another look at the jackknife, Ann Stat, 7, 1, 10.1214/aos/1176344552 · DOI · Paper page
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Klempner, S. J., Fabrizio, D., Bane, S., Reinhart, M., Peoples, T., Ali, S. M., Sokol, E. S., Frampton, G., Schrock, A. B., Anhorn, R., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0244 · Cited by 391
Understanding the tumor microenvironment for effective immunotherapy
Sadeghi Rad, H., Monkman, J., Warkiani, M. E., Ladwa, R., O'Byrne, K., Rezaei, N., & Kulasinghe, A. (2021) · Medicinal Research Reviews · doi:10.1002/med.21765 · Cited by 334
“a fitness advantage in their microenvironment, leading the cell lineage to cancer, while passenger mutations do not offer such a proliferative benefit.(160) Some mutations in the DNA can result in the formation of antigens that are recognized and targeted by the immune system, and so‐called “neoantigens.”
BackgroundManrubia, S., Cuesta, J. A., Aguirre, J., Ahnert, S. E., Altenberg, L., Cano, A. V., Catalán, P., Diaz-Uriarte, R., Elena, S. F., García-Martín, J. A., et al. (2021) · Physics of Life Reviews · doi:10.1016/j.plrev.2021.03.004 · Cited by 88
Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter
Redmer, T. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0854-5 · Cited by 67
“This makes it likely that different mechanisms are involved, predetermined by the oncogenic mutation that is present, albeit mutations in passanger genes might also play a role in that process [47, 48].”
Background
Metadata
- Authors
- McFarland, C. D., Yaglom, J. A., Wojtkowiak, J. W., Scott, J. G., Morse, D. L., Sherman, M. Y., & Mirny, L. A.
- Venue
- Cancer Research
- Published
- 2017-09-14
- Volume
- 77
- Issue
- 18
- Pages
- 4763-4772
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2617489830
- Cited by
- 120
- References
- 10
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- National Cancer Institute (R01CA176326, U54CA193419)
- Cancer Systems Biology Scholars (E25CA180993)
- H. Lee Moffitt Cancer Center and Research Institute (P30-CA076292)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Damaging Effect of Passenger Mutations on Cancer Progression. https://app.cochat.ai/papers/10.1158/0008-5472.can-15-3283-t
- The paper
- McFarland, C. D., Yaglom, J. A., Wojtkowiak, J. W., Scott, J. G., Morse, D. L., Sherman, M. Y., & Mirny, L. A. (2017). The Damaging Effect of Passenger Mutations on Cancer Progression. Cancer Research. https://doi.org/10.1158/0008-5472.can-15-3283-t
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.